BIOMAT Database Logo BIOMAT Database Logo

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. 1998

B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Research Unit, Ness-Ziona Mental Health Center, Israel.

Impulsiveness and aggressiveness may be the most common behavioral correlates of central serotonergic dysfunction. The aim of this study was to determine whether clozapine, an atypical antipsychotic agent with a potent serotonergic antagonistic activity, affects impulsiveness and aggression. Its effects on serum lipids, platelet-poor plasma serotonin (5-HT), and norepinephrine (NE) levels were also studied. Thirty neuroleptic-resistant chronic schizophrenic patients, maintained on clozapine for 1 year, were evaluated for aggressiveness, impulsiveness, and suicidality in comparison with 30 chronic schizophrenic patients maintained on classical antipsychotic agents for the same period of time. Clozapine treatment was associated with less impulsiveness (p < 0.05), aggressiveness (p < 0.01) and fewer suicidal attempts (p < 0.05). Serum triglycerides and plasma NE levels were significantly higher (p < 0.01 and p < 0.0001, respectively) in the patients treated with clozapine, as compared with patients treated with classical neuroleptic drugs. The authors conclude that long-term clozapine treatment may be effective in controlling aggressive, impulsive, and suicidal behavior in neuroleptic-resistant chronic schizophrenic patients. The elevated plasma NE levels in patients treated with clozapine as compared to those treated with classical neuroleptic drugs may be relevant for the anti-aggressive/antisuicidal activity of clozapine.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000092864 Suicide Prevention Specific strategies for averting suicides. These include mental HEALTH PROMOTION and monitoring PSYCHOLOGICAL WELL-BEING and other intervention programs targeting susceptible individuals. Suicide Awareness,Awareness, Suicide,Prevention, Suicide,Suicide Preventions
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels.
January 1997, Therapie,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients.
October 1997, Clinical neuropharmacology,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients.
January 1983, Psychopharmacology,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Serum triglyceride levels in patients treated with clozapine.
September 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients.
February 2004, Schizophrenia research,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Total and free plasma neuroleptic levels in schizophrenic patients.
December 1984, Psychiatry research,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients.
January 2017, Revista de psiquiatria y salud mental,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Low serum neuroleptic levels predict relapse in schizophrenic patients.
September 1982, Archives of general psychiatry,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients.
January 2005, Neuropsychobiology,
B Spivak, and S Roitman, and Y Vered, and R Mester, and E Graff, and Y Talmon, and N Guy, and N Gonen, and A Weizman
Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics.
September 2009, Neuroscience letters,
Copied contents to your clipboard!